FOLD News and Press, Amicus Therapeutics Inc. From 01/09/20

Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations Recently Received in Brazil, Colombia and Taiwan Galafold on Track for $500M Revenu...

Amicus Therapeutics ( FOLD -0.5% ) announces that it completed enrollment last quarter in its Phase 3 clinical trial, PROPEL , evaluating chaperone replacement therapy AT-GAA in patients with an inherited metabolic disorder called Pompe disease , characterized by the buildup of glycoge...

123 Patients Enrolled in Phase 3 PROPEL Study – Enrollment Completed in 4Q2019 Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition of Full Clinical Results in 1H2021 to Support Full Approval under Fast Track ...

Q4 2019 has been the best quarter ([[IBB]] up 22.5% [[XBI]] up 26.7%) for biotech investors since Q1 2015, which was the top of 2014-2015 rally. This 20+% rally is largely attributed to Fed's overall easing stance, increased mergers & acquisitions, positive regulatory backdrop, solid trial...

Gainers: NBR   +2.7% . FVRR   +2.3% . GVA   +1.1% . More news on: Nabors Industries Ltd., Fiverr International Ltd., Granite Construction Incorporated, Stocks on the move, , News on ETFs Read more ...

Capital Structure Price per share: ~$21 | Market capitalization: ~$650M Cash and cash equivalents: $206M | Debt: NA Cash burn: ~$20M/quarter | Cash runway: into 2021 Commercial assets: 0 | Phase 3: 0 | Phase 2: 1 | Phase 1: 2 Introduction AVROBIO ( AVRO ) is a phase 2 biotechn...

Continuing with the series of articles on gene therapy, this article will discuss the various delivery methods for gene therapies with a focus on viral vectors. What is transgene? A transgene is a new therapeutic DNA segment that is to be inserted into the host cell. In addition to the g...

Amicus Therapeutics, Inc. (FOLD) Q3 2019 Results Conference Call November 11, 2019 08:30 AM ET Company Participants Sara Pellegrino - VP, IR John Crowley - Chairman and CEO Bradley Campbell - President and COO Daphne Quimi - CFO Dr. Jay Barth - Chief Medical Officer Dr. Jef...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2019 Q3 earnings Read more ...

Carbonite (NASDAQ: CARB ) +25%  on being acquired for $1.42B. More news on: Carbonite, Inc., Qurate Retail, Inc., Assembly Biosciences, Inc., Stocks on the move, Read more ...